Melody Smith earned her MD with Distinction in Research from the University of Texas Southwestern Medical School in Dallas in 2009 and she finished residency in Internal Medicine at UT Southwestern Medical Center in 2012. She completed a fellowship in Hematology & Oncology at Memorial Sloan Kettering Cancer Center in 2015, after which she joined the Adult Bone Marrow Transplant Service.
Her research focuses on using donor CD19 chimeric antigen receptor (CAR) T cells following allogeneic hematopoietic cell transplant to decrease relapse without inducing graft versus host disease (GVHD). Melody utilizes a mouse model to investigate strategies to optimize the administration of donor CD19 CAR T cells. This research has the potential to benefit patients with CD19 positive hematologic malignancies as it would be a strategy to decrease the potential for disease relapse while limiting toxicity due to GVHD.
European Society for Blood and Marrow Transplantation (EBMT), Best Basic Science
American Society of Hematology (ASH), Abstract Achievement Award (2016)
NIH Loan Repayment Award (LRP) (2016, 2019)
European Hematology Association and the American Society of Hematology Translational Research Training in Hematology (2015)
American Society of Bone Marrow Transplant Clinical Research Training Course (2015)
Cycle for Survival (2019- )
Robert Wood Johnson Foundation, ASH-Harold Amos Medical Faculty Development Program (AMFDP) (2018- )
Damon Runyon Cancer Research Foundation, Physician-Scientist Training Award (2017- )
Burroughs Wellcome Fund, Postdoctoral Enrichment Program Award (2017- )
Parker Institute for Cancer Immunotherapy (PICI), Pilot Grant (PI) (2017- 2019)
American Society for Blood and Marrow Transplantation (ASBMT), New Investigator Award (2016- 2018)
NIH Diversity Supplement (R01 AI 100288) (2014- 2016)
NIH T32 Institutional Clinical Scholars Training Grant (2013- 2015)
The Lymphoma Foundation Mortimer J. Lacher Grant (2013- 2015)
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Melody Smith discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures